期刊文献+

替加环素治疗泛耐药鲍曼不动杆菌及肠杆菌科细菌的医院获得性肺炎的疗效 被引量:7

Efficacy of tigecycline in the treatment of XDRAB and XDRE HAP
下载PDF
导出
摘要 目的评价替加环素治疗泛耐药(extensively drug resistant,XDR)的鲍曼不动杆菌(Acinetobacter baumannii,AB)及肠杆菌科细菌(Enterobacteriaceae,E)医院获得性肺炎(Hospital Acquired Pneumonia,HAP)疗效。方法通过回顾我院两年来使用含替加环素及不含替加环素方案治疗XDRAB及XDRE的HAP患者治疗及预后,对照他们转归是否存在差异。结果组间有效率及死亡率无显著性差异(P>0.05);使用替加环素方案继发铜绿假单胞菌感染显著较多。结论使用替加环素治疗XDRAB及XDRE的HAP无法改善患者有效率及死亡率。 Objective To evaluate the efficacy of tigecycline in the treatment of extensively drug resistant (XDR) acinetobaeter baumannii (AB) and Enterobaeteriaceae (E) hospital acquired pneumonia (HAP). Methods The medical records of patients with XDRAB and XDRE HAP, who had been treated with tigecycline and without tigeeycline, were retrospectively reviewed. The clinical curative effect was compared between the two groups. Results There was no significant difference in total effective rate and mortality between the two groups ( P 〉 0.05 ). The in- cidence of pseudomonas aeruginosa infection was higher in the study group than in the control group. Conclusion Tigecycline can not increase effective rate and reduce mortality in the treatment of XDRAB and XDRE HAP.
出处 《临床肺科杂志》 2016年第4期690-693,共4页 Journal of Clinical Pulmonary Medicine
关键词 替加环素 XDR 鲍曼不动杆菌 肠杆菌科细菌 肺部感染 疗效 tigecycline extensively drug resistant acinetobacter baumannii enterobacteriaceae pulmonary infection efficacy
  • 相关文献

参考文献13

  • 1Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resist- ant, extensively drug-resistant and pandrug-resistant bacteria: aninternational expert proposal for interim standard definitions for ac- quired resistance[J]. Clin Microbiol Infect, 2012, 18(3) : 268 -281.
  • 2李耘,吕媛,薛峰,张秀珍,胡云建,于庭,胡志东,赵建宏,潘世扬,胡必杰,俞云松,邓秋连,李艳,刘文恩,周玲,费樱,府伟灵,徐修礼,裴凤艳,孟灵,季萍,汤进,郑波,刘健,杨维维,张佳.卫生部全国细菌耐药监测网(Mohnarin)2011-2012年革兰阳性菌耐药监测报告[J].中国临床药理学杂志,2014,30(3):251-259. 被引量:115
  • 3陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85. 被引量:848
  • 4Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbap- enemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions [ J ]. Clin Microbiol Rev, 2012, 25(4) : 682 -707.
  • 5De Freitas ER. Profile and severity of the patients of intensive care units:prospective application of the APACHE lI index [ J ]. Revista Latino-Ameficana De Enfermagem, 2010, ( 03 ) : 317 - 323.
  • 6Soo-Youn Moon, Kyong Ran Peck, Hyun-Ha Chang,et al. Clinical Experience of Tigecycline Treatment in Infections Caused by Ex- tensively Drug-Resistant Acinetobacter spp[J]. Microbial Drug Resistance, 2012,18 (10) :562 - 566.
  • 7Paul C. McGoverna, Michele Wiblea, Ahmed E1-Tahtawya, et al. All-canse mortality imbalance in the tigecycline phase 3 and 4 clinical trials [ J ]. International Journal of Antimicrobial Agents, 2013,41(5) : 463 - 467.
  • 8Vasilev K, R eshedko G, O rasan R, et al. A phase 3, open-la- bel, non-comparative study of tigecycline in the treatment of pa- tients with selected serious infections due to resistant Gram-nega- tive organisms including Enterobacter species, Acinetobacter bau- mannii and Klebsiella pneumoniae [ J ]. J Antimicrob Chemother, 2008 ,62( Suppl 1) : 129 - 140.
  • 9Dafna Yahav, Adi lador, Mical Paul, et al. Efficacy and safety of tigecycline : a systematic review and meta-analysis [ J ]. J Antimi- crob Chemother,2011,66(9) : 1963 - 1971.
  • 10Burkhardt O, Ranch K, Kaever V, et al. Tigecycline possibly un- derdosed for the treatment of pneumonia: a pharmacokinetic view- point[ J]. Int J Antimicrob Agents 2009, 34( 1 ) : 101 - 102.

二级参考文献18

共引文献961

同被引文献50

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部